ChiCTR2000029806 (camrelizumab), 0 ChiCTR2000029806
anti-PD-1 antibody vs. standard of care
COVID-19 severe or critically
COPERNICO, 0 NCT04335305
anti-PD-1 antibody vs. tocilizumab
COVID-19 severe or critically
NCT04317040, 0 NCT04317040
CD24Fc vs. placebo
COVID-19 severe or critically
Sean, 2020
convalescent plasma treatment vs. control
COVID-19 severe or critically
Hegerova, 2020
convalescent plasma treatment vs. control
COVID-19 severe or critically
Duan, 2020
convalescent plasma treatment vs. control
COVID-19 severe or critically
Joyner, 2020 NCT04338360
convalescent plasma treatment vs. convalescent plasma treatment
COVID-19 severe or critically
Gonzales, 2021 NCT04381858
convalescent plasma treatment vs. immunoglobulin therapy
COVID-19 severe or critically
PLASM-AR, 0 NCT04383535
convalescent plasma treatment vs. placebo
COVID-19 severe or critically
O’Donnell, 2021 NCT04359810
convalescent plasma treatment vs. placebo
COVID-19 severe or critically
ILBS-COVID-02 (Bajpai M), 2020 NCT04346446
convalescent plasma treatment vs. placebo
COVID-19 severe or critically
NCT04400058, 0 NCT04400058
convalescent plasma treatment vs. placebo
COVID-19 severe or critically
PlasmAr, 2020 NCT04344535
convalescent plasma treatment vs. placebo
COVID-19 severe or critically
Sekine (PLACOVID), 2021 NCT04547660
convalescent plasma treatment vs. standard of care
COVID-19 severe or critically
Rasheed, 2020
convalescent plasma treatment vs. standard of care
COVID-19 severe or critically
PICP19 (Ray), 2020 CTRI/2020/05/025209
convalescent plasma treatment vs. standard of care
COVID-19 severe or critically
CP-COVID-19, 2021 NCT04332835
convalescent plasma treatment vs. standard of care
COVID-19 severe or critically
AlQahtani, 2020 NCT04356534
convalescent plasma treatment vs. standard of care
COVID-19 severe or critically
Ray, 2022
convalescent plasma treatment vs. standard of care
COVID-19 severe or critically
COV2-CP, 0 NCT04385043
convalescent plasma treatment vs. standard of care
COVID-19 severe or critically
REMAP-CAP (plasma), 2021 NCT02735707
convalescent plasma treatment vs. standard of care
COVID-19 severe or critically
RECOVER, 2021 EudCT 2020-001632-10
convalescent plasma treatment vs. standard of care
COVID-19 severe or critically
Bihariesingh-Sanchit (SuriCovid), 2021 ISRCTN18304314
convalescent plasma treatment vs. standard of care
COVID-19 severe or critically
Pouladzadeh, 2021 IRCT20200310046736N1
convalescent plasma treatment vs. standard of care
COVID-19 severe or critically
ChiCTR2000030627, 0 ChiCTR2000030627
convalescent plasma treatment vs. standard of care
COVID-19 severe or critically
Li, 2020 ChiCTR2000029757
convalescent plasma treatment vs. standard of care
COVID-19 severe or critically
CAPSID, 2021 NCT04433910
convalescent plasma treatment vs. standard of care
COVID-19 severe or critically
Lopardo, 2021 NCT04494984
equine polyclonal antibodies INM005 vs. placebo
COVID-19 severe or critically
Kalil (ACTT-3), 2021 NCT04492475
IFN beta-1a vs. placebo
COVID-19 severe or critically
Darazam (COVIFERON Interferon beta-1a), 2021 NCT04343768
IFN beta-1a vs. standard of care
COVID-19 severe or critically
Davoudi-Monfared, 2020 IRCT20100228003449N2
IFN beta-1a vs. standard of care
COVID-19 severe or critically
Darazam (COVIFERON Interferon beta-1b), 2021 NCT04343768
IFN beta-1b vs. standard of care
COVID-19 severe or critically
Rahmani, 2020 IRCT20100228003449N2
IFN beta-1b vs. standard of care
COVID-19 severe or critically
Gharebaghi, 2020 IRCT20200501047259N1
immunoglobulin therapy vs. placebo
COVID-19 severe or critically
Raman, 2021 CTRI/2020/06/026222
immunoglobulin therapy vs. standard of care
COVID-19 severe or critically
Tabarsi, 2020 IRCT20151227025726N2
immunoglobulin therapy vs. standard of care
COVID-19 severe or critically
